ASCO Launches Cancer.Net Mobile, a New App for iPhone, iPad, and iPod Touch

The American Society of Clinical Oncology (ASCO), the world's leading professional organization representing cancer physicians, released Cancer.Net Mobile for the iPhone, iPad, and iPod Touch - a free app designed by oncologists to help people with cancer and their caregivers plan and manage cancer treatment and care. The app includes comprehensive, doctor-approved information on more than 120 cancer types, together with a package of interactive tools for patients. Cancer.Net Mobile is available for download in Apple's App Store and is the mobile companion to ASCO's award-winning Cancer.Net website.

"Cancer.Net Mobile puts up-to-date, accurate cancer information and interactive tools at the fingertips of people living with cancer and their families and caregivers, wherever they are," said ASCO CEO Allen S. Lichter, MD. "Cancer.Net Mobile was developed by leading cancer doctors with patients and their caregivers in mind, to help them take charge of their cancer care and get the most out of doctor's visits."

In addition to its comprehensive cancer guides covering more than 120 common and rare types of cancer, Cancer.Net Mobile includes interactive tools for patients and caregivers to:

  • Keep track of questions to ask their doctors, record voice answers, and choose from frequently-asked questions suggested by Cancer.Net experts
  • Save important information about prescribed medications, including photos of medicine labels and bottles (on camera-enabled devices)
  • Track the time and severity of symptoms and side effects during treatment, to aid in reporting them during doctor’s visits
  • Learn about new cancer care topics through weekly podcast and video interviews with ASCO member physicians

Cancer.Net Mobile offers a portable version of the extensive cancer information library available on the Cancer.Net website, with expert information about treating cancer, managing side effects, managing the cost of care, and coping with a cancer diagnosis. All Cancer.Net content is reviewed for accuracy and completeness by an editorial board composed of more than 150 medical, surgical, radiation, and pediatric oncologists; oncology nurses; social workers; and patient advocates. This ensures that the cancer information provided reflects the latest advances in cancer science and clinical practice. Cancer.Net is supported by the Conquer Cancer Foundation of ASCO.

Cancer.Net Mobile is available for download in Apple's App Store at http://itunes.com/apps/cancernetmobile (iTunes required). It is compatible with iPhone, iPad, and iPod Touch devices running iOS version 3.2 or later. Cancer.Net Mobile is a free tool provided by ASCO. Cancer.Net Mobile app updates will be issued regularly as the cancer guide content is updated.

About ASCO
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With nearly 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs, and peer-reviewed journals.

About the Conquer Cancer Foundation
The Conquer Cancer Foundation is working to create a world free from the fear of cancer by funding breakthrough research, by sharing knowledge with physicians and patients worldwide, and by supporting initiatives to ensure that all people have access to high-quality cancer care. Working in close collaboration with a global network of top scientists and clinicians, as well as leading advocacy and research organizations, the Foundation draws on the passion and expertise of the nearly 30,000 oncology professionals who are members of its partner organization, the American Society of Clinical Oncology (ASCO).

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...